Pixium Vision - Edison Group

Overview
Price performance
Financials
Research
Sector insights
Thematics

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Latest Insights

View More

Healthcare |
Flash note

10.10.23

Pixium Vision — Safeguard proceedings underway

Healthcare |
Update

11.08.23

Pixium Vision — Shareholder loan extends runway

Healthcare |
Update

02.05.23

Pixium Vision — Focusing on reaching the PRIMAvera milestone

Healthcare |
Flash note

31.03.23

Pixium Vision — Breakthrough designation provides validation

Pixium-Vision_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(6.9)	(92.8)	(97.1)
Relative	(13.0)	(92.8)	(97.3)
52 week high/low	€0.2/€0.0

Financials

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2021A	2.7	(9.7)	(10.9)	(23.06)	N/A	N/A
2022A	2.0	(11.5)	(10.3)	(21.09)	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A

Update

Healthcare

07.03.22

Pixium Vision — Moving ahead as expected

Update

Healthcare

15.12.21

Pixium Vision — PRIMAvera recruitment timing pushed out

Flash note

Healthcare

20.10.21

Pixium Vision — Three-year data confirms continued Prima safety

Outlook

Healthcare

05.10.21

Pixium Vision — Advancing towards sight restoration in dry-AMD

edison tv

Healthcare

27.08.21

Pixium Vision – executive interview

Update

Healthcare

16.07.21

Pixium Vision — Capital increase strengthens funding runway

Update

Healthcare

08.06.21

Pixium Vision — Signalling an intent to access US investors

Update

Healthcare

07.04.21

Pixium Vision — Back to basics as Second Sight deal is called off

Flash note

Healthcare

26.03.21

Pixium Vision — Second Sight $28m financing adds clouds to deal

Update

Healthcare

03.03.21

Pixium Vision — FY20 results in line, awaiting merger updates

edison tv

Healthcare

03.02.21

Pixium Vision – Edison Open House interview

Update

Healthcare

11.01.21

Pixium Vision — Pixium Vision to combine with Second Sight

Update

Healthcare

25.11.20

Pixium Vision — ANSM approval to start PRIMAvera pivotal study

Update

Healthcare

29.10.20

Pixium Vision — Q3 results in line, awaiting pivotal study approval

Flash note

Healthcare

28.07.20

Pixium Vision — H120 results broadly in line

Update

Healthcare

09.07.20

Pixium Vision — €7.3m capital increase completed

Outlook

Healthcare

22.06.20

Pixium Vision — Restoring eyesight in advanced Dry-AMD

Update

Healthcare

06.04.20

Pixium Vision — Prima 2 18-month data shows strong promise

Update

Healthcare

26.03.20

Pixium Vision — Strategy in place to mitigate COVID-19 effects

Flash note

Healthcare

05.03.20

Pixium Vision — Successful Prima activation in first US patient

Update

Healthcare

19.02.20

Pixium Vision — Wrapping up 2019 with a solid financial position

Update

Healthcare

27.01.20

Pixium Vision — US feasibility study now underway

research

Healthcare

07.11.19

Pixium Vision — Pixium to raise up to €10m to advance Prima

Flash note

Healthcare

07.11.19

Pixium Vision — Pixium to raise up to €10m to advance Prima

Update

Healthcare

28.10.19

Pixium Vision — Building feasibility data on way to pivotal study

Update

Healthcare

06.08.19

Pixium Vision — Refining Prima system before starting pivotal trial

Flash note

Healthcare

02.05.19

Pixium Vision — Pixium appoints new CEO

Outlook

Healthcare

12.04.19

Pixium Vision — Prima gearing up for a pivotal year

Update

Healthcare

19.02.19

Pixium Vision — Financials in line as Prima advances

research

Healthcare

19.02.19

Pixium Vision — Financials in line as Prima advances

Flash note

Healthcare

11.01.19

Pixium Vision — Positive interim six-month Prima data

Update

Healthcare

17.12.18

Pixium Vision — Encouraging signs in Prima EU feasibility study

research

Healthcare

08.08.18

Pixium Vision — H118 update reflects continued Prima progress

Outlook

Healthcare

08.03.18

Pixium Vision — Focus shifts to Prima as human trials proceed

Flash note

Healthcare

30.01.18

Pixium Vision — Successful Prima activation in first patient

Update

Healthcare

24.10.17

Pixium Vision — Pixium cleared to start EU Prima feasibility study

research

Healthcare

05.10.17

Pixium Vision — Pixium seeks to address short Iris II lifespan

Flash note

Healthcare

26.05.17

Pixium Vision — Forfait Innovation decision postponed

Outlook

Healthcare

30.03.17

Pixium Vision — Key advancements for Iris II and Prima in 2017

Flash note

Healthcare

12.01.17

Pixium Vision — Update 12 January 2017

Update

Healthcare

19.10.16

Pixium Vision — Update 19 October 2016

Update

Healthcare

27.07.16

Pixium Vision — Update 27 July 2016

Update

Healthcare

15.07.16

Pixium Vision — Update 15 July 2016

Update

Healthcare

25.02.16

Pixium Vision — Update 24 February 2016

Update

Healthcare

08.01.16

Pixium Vision — Update 7 January 2016

Initiation

Healthcare

22.09.15

Pixium Vision — Update 22 September 2015